- Home
- HALO vs NCLH Comparison
HALO vs NCLH Comparison
Compare HALO & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HALO
- NCLH
- Stock Information
- Founded
- HALO 1998
- NCLH 1966
- Country
- HALO United States
- NCLH United States
- Employees
- HALO N/A
- NCLH N/A
- Industry
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- NCLH Marine Transportation
- Sector
- HALO Health Care
- NCLH Consumer Discretionary
- Exchange
- HALO Nasdaq
- NCLH Nasdaq
- Market Cap
- HALO 7.4B
- NCLH 7.1B
- IPO Year
- HALO N/A
- NCLH 2013
- Fundamental
- Price
- HALO $54.54
- NCLH $17.32
- Analyst Decision
- HALO Buy
- NCLH Buy
- Analyst Count
- HALO 9
- NCLH 18
- Target Price
- HALO $63.56
- NCLH $26.18
- AVG Volume (30 Days)
- HALO 3.3M
- NCLH 15.6M
- Earning Date
- HALO 05-06-2025
- NCLH 04-30-2025
- Dividend Yield
- HALO N/A
- NCLH N/A
- EPS Growth
- HALO 55.40
- NCLH 120.77
- EPS
- HALO 3.76
- NCLH 1.77
- Revenue
- HALO $1,084,306,000.00
- NCLH $9,415,989,000.00
- Revenue This Year
- HALO $25.77
- NCLH $8.67
- Revenue Next Year
- HALO $18.01
- NCLH $9.74
- P/E Ratio
- HALO $14.51
- NCLH $9.78
- Revenue Growth
- HALO 25.64
- NCLH 5.57
- 52 Week Low
- HALO $42.01
- NCLH $14.21
- 52 Week High
- HALO $70.51
- NCLH $29.29
- Technical
- Relative Strength Index (RSI)
- HALO 44.48
- NCLH 44.30
- Support Level
- HALO $52.43
- NCLH $18.86
- Resistance Level
- HALO $54.26
- NCLH $19.68
- Average True Range (ATR)
- HALO 3.42
- NCLH 0.54
- MACD
- HALO -0.49
- NCLH -0.06
- Stochastic Oscillator
- HALO 30.60
- NCLH 18.77
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
About NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 66,500). It operates 32 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 41,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.